Wu, Tzong-YowTzong-YowWuTsai, Wan-TingWan-TingTsaiChen, Kai-HsiangKai-HsiangChenHuang, Szu-TingSzu-TingHuangHuang, Chun-FuChun-FuHuangKuo, Po-HsienPo-HsienKuoMING-JUI TSAIWANG-DA LIUKUAN-YIN LINYU-SHAN HUANGARISTINE CHENGPAO-YU CHENHSIN-YUN SUNHUAI-HSUAN HUANGTAI-CHUNG HUANGSHANG-JU WUMING YAOJANN-TAY WANGWANG-HUEI SHENGCHIEN-CHING HUNGYEE-CHUN CHENSHAN-CHWEN CHANG2024-03-252024-03-252024-03-0816841182https://scholars.lib.ntu.edu.tw/handle/123456789/641286Patients with hematological malignancies (HM) were at a high risk of developing severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess the clinical outcome of COVID-19 in hospitalized patients with HM.enLymphoma; Respiratory failure; SARS-CoV-2; Stem cell transplant; Vaccination[SDGs]SDG3journal article10.1016/j.jmii.2024.03.001384800932-s2.0-85187570370